Topoisomerase II (Topo II)-inhibiting antineoplastic agents, such as etoposide and doxorubicin are among the most effective antitumor drugs currently available for the treatment of human cancers. [2] [3] [4] [5] [6] These agents are shown to induce the accumlation of DNA-topo II cleavable complex (cleavable complex) which causes tumor cell death.
7)
Etoposide (1) , an extensively used clinical topo II inhibitor elicits significant antitumor activity against a wide variety of neoplasms, including germ cell malignancies, small cell lung cancer (SCLC), non-Hodgkin's lymphomas, leukemias, Kaposi's sarcoma, neuroblastoma and soft-tissue sarcomas. 2, 3) Use of etoposide and cisplatin (or carboplatin) is the standard therapy for patients with SCLC. 4) Doxorubicin is a topo II inhibitor with various activities such as nuclear helicase inhibitory activity 8) and free-radical formation activity. 9) Doxorubicin is a primary drug for the treatment of patients with lymphomas, breast cancer and sarcomas. ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) and CHOP (cyclophosphamide, doxorubicin and prednisone) are used as the standard therapy for advanced Hodgkin's lymphoma and intermediate-grade non-Hodgkin's lymphoma, respectively. 5, 6) However, these drugs are not used as therapeutics for commonly occurring solid tumors such as non-small-cell lung cancer (NSCLC), colon cancer, gastric cancer and pancreatic cancer.
Continuous effort is being made to apply topo II inhibitors for the treatment of various solid tumors. Amurubicin, 10, 11) launched on the market in Japan in 2002, shows efficacy against NSCLC and SCLC. Several topo II inhibitors are currently under clinical studies against solid tumors. [12] [13] [14] Amonafide (3), 15) which is the basis of our drug design in this program, is also a topo II inhibitor on which intensive clinical studies were conducted in the mid 1990s. In 2003, a phase study was launched in the United States to evaluate amonafide as a potential therapeutic for solid tumors. 16) The objective of our study is to create a structurally novel topo II inhibitor effective against various solid tumors such as NSCLC, colon, gastric and pancreatic cancers. This paper describes our medicinal chemistry program which leads to the discovery of a novel pyrimidocarbazole compound 26 (ER37326) with high in vitro and in vivo potencies.
Chemistry
The structures of synthesized compounds for biological evaluation are presented in Table 1 . The synthesis of pyrimidoacridones 6-10 is summarized in Chart 1. The amides 30a-c were prepared from corresponding 9-oxoacridan-4-carboxylic acids 29a-c. 17, 18) Compounds 29a-c were treated with N,NЈ-carbodiimidazole (CDI) in dimethylformamide (DMF) followed by N,N-dimethylethylenediamine to produce amide 30a-c respectively. Cyclization of 30a-c provided 6, 19) 31b and 31c respectively. Cyclization of 30a and 30b was carried out by treatment with sodium hydride followed by ethyl chloroformate, instead of the use of phosgene as previously reported in the synthesis of 6. 19) Cyclization of 30c was conducted by using Hunig's base and ethyl chloroformate.
The 5-or 9-nitro derivatives 31b and 31c were hydrogenated into the amino derivatives 7 and 9, which were then acetylated with acetic anhydride to yield acetylamino derivatives 8 and 10 respectively. Ring opening reaction on 8 by potassium carbonate (K 2 CO 3 ) was carried out to provide 27.
The synthesis of pyrimidophenoxazines 11 and 12 (Chart 2) involved the coupling reaction of 1-chloro-2,4-dinitrobenzene and 3-hydroxyanthranilic acid in the presence of sodium acetate to yield 2-(2,4-dinitrophenylamino)-3-hydroxy benzoic acid 34. Cyclization of 34 was conducted in a similar manner to the reported procedure for the synthesis of 7-nitro-10H-phenoxazine. 20) Compound 34 was heated in the presence of K 2 CO 3 to give 7-nitro-10H-phenoxazine-1-carboxylic acid 35. Then 35 was treated with CDI followed by N,N-dimethylethylenediamine to produce amide 36 which was cyclized in the presence of triethylamine and ethyl chloroformate and then hydrogenated into the amino derivative 11 before acetylation to acetylamino derivative 12.
The syntheses of pyrimidocarbazoles 13-26 and 28 are shown in Charts 3-6. As shown in Chart 3, 9H-carbazole-1-carboxylic acid 39a was synthesized by slight modification of the reported procedure. 21) Fisher cyclization reaction of cyclohexanone and 2-hydrazino benzoic acid hydrochloride in acetic acid (AcOH) under reflux yielded 5,6,7,8-tetrahydro-9H-carbazole-1-carboxylic acid in one pot, which was aromatized by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to 9H-carbazole-1-carboxylic acid 39a. Treatment of the 39a with potassium nitrate in sulfuric acid afforded the crude mixture of the mono-nitro regio isomers 39b and 39c, and then the mixture was amidated to afford the mixture of 40b and 40c. Compounds 40b and 40c were isolated by separation with silica gel (SiO 2 ) column chromatography. Each of them was cyclized into pyrimidocarbazoles 42b and 42c by treatment with sodium hydride followed by ethyl chloroformate. They were converted into amino and acetylamino derivatives 14-17 in a manner similar to the synthesis of pyrimidoacridones.
The 8-aminopyrimidocarbazole derivative 14 and its free base 44b were used as key intermediates to produce various 8-substituted derivatives (Charts 3, 4). Compound 14 was mesylated with methanesulfonic anhydride to yield 22. Compound 25 was prepared from 44b by acylation with n-butyryl chloride. 44b was diazotized, and then hydrolyzed in the presence of CuI and Cu 2 O to give hydroxy derivative 19, which was converted into methoxy derivative 20 with sodium hydride and methyl iodide. Compound 23 was prepared by heating 44b with 2,5-dimethoxy-tetrahydrofuran in AcOH.
As shown in Chart 5, 8-methyl derivative 18 was prepared by the Fisher cyclization reaction of 4-methylcyclohexanone and 2-hydrazino benzoic acid hydrochloride followed by the same procedure for the synthesis of 13.
Friedel-Craft reaction of 39a with acetic anhydride or nbutyryl chloride in the presence of AlCl 3 gave the desired 8-acylated products 46a and 46b respectively almost exclusively (Chart 6). Compounds 46a and 46b were converted into 26 and 24 in a similar manner described above.
Results and Discussion
The results of in vitro growth inhibitory activity against murine leukemia P388 and human oral cancer KB and DNAprotein cross-linking formation activity of compounds 6-28 and reference compounds are presented in Table 1 and Fig. 2 . DNA-protein cross-linking formation is considered to be an indicator for the ability of a compound to stabilize the cleavable complex of the compound, DNA, and topo II.
The results of the in vivo activity of selected compounds against P388 and M5076 are shown in Table 2 and Table 3 respectively.
At the commencement of our program, we evaluated in vitro growth inhibitory activities of amonafide (3) , N-acetylamonafide (4) and unsubstituted 1,8-naphthalic imide (5) to examine the importance of the amino substituent of amonafide and the acetylamino substituent of N-acetylamonafide. Amonafide and N-acetylamonafide showed higher in vitro growth inhibitory activities than the unsubstituted 1,8-naphthalic imide (5) ( Table 1) .
Based on the above results of the amino and acetylamino substituent playing a key role in their activities, we designed and synthesized compounds (7-10) with pyrimidoacridone chromophore 19, 22) bearing the amino or acetylamino substituent on 5-or 9-position. Compound 6, previously reported by Antonini et al. 19) was also prepared and evaluated. In comparison to 6, compounds 8 and 10 showed almost equal activities in the in vitro P388 model and higher activities in vitro KB model.
Compounds 6, 8, 10 were evaluated in the in vivo P388 model (Table 2) . Compound 8 showed the most potent activity among them with a maximum increase in lifespan (ILS) of Ͼ125% at 25 mg/kg/d. The superiority of 8 over 6 in their activities in vivo P388 could be attributed to the higher activity of 8 in the DNAprotein cross-linking formation activities than 6.
As we found an active compound 8 in in vivo P388 model, this compound was evaluated in in vivo solid tumor model M5076 which is a more appropriate model for screening compounds effective against solid tumors. As a result, compound 8 also showed good efficacy in in vivo M5076 model with 18% T/C (Table 3) .
While 8 was attractive because of its efficacy, it indicated significant body weight loss in mice, (relative body weight (RBW) on day 7 was 0.78.), with chemical instability even under neutral condition, 23) which is an unwanted property as a drug.
Many anticancer topo II inhibitors, such as amonafide, amsacrine, doxorubicin, and ellipticine 24) contain a planer chromophore which can intercalate into the DNA helix. Since we speculated that these pyrimidoacridones are included in this class of intercalative topo II inhibitors, replacement of the acridone portion by other planer tricyclic chromophore was considered to be possible. Therefore we thought to explore other planer chromophores to improve the biological potency and chemical stability. Thus the novel pyrimidophenoxadines 11, 12 and pyrimidocarbazoles 13-26 were designed, synthesized, and evaluated. 1074 Vol. 52, No. 9
Chart 6. Synthesis of Pyrimidocarbazoles (IV) In the subset of the amino and acetylamino substituentcontaining analogues (Table 1) , pyrimidophenoxadines and pyrimidocarbazoles were much more potent than their corresponding pyrimidoacridones in in vitro growth inhibitory activity and DNA-protein cross-linking formation assay (7 vs. 11 vs. 14, 8 vs. 12 vs. 15, 9 vs. 16, 10 vs. 17). In addition, pyrimidocarbazoles were chemically more stable than pyrimidoacridones. 25) Although pyrimidophenoxadines were highly potent in vitro, in vivo efficacy of 12 was elusive because of its relatively severe toxicity. In most cases, the body weight of mice treated with our compounds recovered after the termination of drug administration. In the experiment, the body weight of mice treated by 12 continued to decrease even after day 7 with eventual death.
In the subset of pyrimidocarbazoles, the amino and acetylamino substituents contributed to their potency on the basis of in vitro growth inhibitory activities against P388 cells (13 vs. 14-17). 5-Substitution contributed more to the in vitro potency against both of P388 and KB cells than 8-substitution (14 vs . 16, 15 vs. 17) . In vivo, this trend reversed (Table  3) . Compounds 14 and 15 were effective at a dose which did not cause the serious body weight decrease observed in case of 8. However, 17 did not show potent in vivo activity.
This result indicated that 8-substitution in pyrimidocarbazoles is more favorable in terms of their potency in the M5076 model than 5-substitution. This trend is similar to the in vivo SAR of pyrimidoacridones in which 9-acetylamino 8 was more potent than 5-acetylamino 10. Compound 27 was inactive in vitro, indicating the importance of pyrimidoacridone chromophore.
Based on the fact that 8-substituted pyrimidocarbazoles 14 and 15 are effective in vivo, other kinds of substitutent on position 8 of pyrimidocarbazole were further investigated (18) (19) (20) (21) (22) (23) (24) (25) (26) .
In in vitro experiments, 19, 24, 25, and 26 (ER37326) showed similar or higher activity than 14 and 15.
As a result of screening using the M5076 model, we found ER-37326 with efficacy of 42% T/C at 3.13 mg/kg/d and 13% T/C at 6.25 mg/kg/d without significantly affecting the body weight, and its potency surpassed that of etoposide. DNA-protein cross-linking was detected in P388 cells treated with 26 (ER37326) as shown in Table 1 No. Dose
No. Dose T/C (%) RBW Tox (ER37326). This result is consistent with that derived from the DNA-protein cross-linking assay ( Fig. 2) , in which DNAprotein cross-linking was not observed at 50 mM of 26 (ER37326), indicating DNA-topo II cleavable complex in P388 cells was induced by 26 (ER37326).
Conclusion
As part of a series of studies to discover potent topo II inhibitors, novel pyrimidoacridones, pyrimidophenoxadines, and pyrimidocarbazoles were synthesized and evaluated in the present study. The pyrimidocarbazoles possessed the most potent in vitro and in vivo antitumor activities.
Of these, 26 (ER-37326), in particular, showed more potent efficacy than etoposide without severe toxicity in the in vivo solid tumor model (M5076). In conclusion, we have found a novel lead compound 26 (ER-37326) worthy of further investigation as a potent anticancer agent against solid tumors.
Experimental
Syntheses of Compounds Melting points (mp) were measured using a Yanako melting point apparatus and are uncorrected. The proton nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a varian Unity 400 (400 MHz) spectrometer or Mercury 400 (400 MHz) spectrometer, and chemical shifts are expressed in ppm downfield from tetramethylsilane (TMS) as an internal standard unless otherwise stated. Mass spectra (MS) were obtained on a SSQ 7000 mass spectrometer. High resolution mass spectra (HR-MS) were obtained on a Q-Tof Ultima global mass spectrometer (micromass U.K.). Elemental analysis was performed with vario EL or vario ELIII or Yanaco MT-3 at Toray Research Center, or Yanaco MT-5 at the Analytical Chemistry Section of Eisai Research Laboratories. Samples for elemental analysis were dried under reduced pressure at 30°C for 2 h, using a drying apparatus (MINI drier; Yazawa, 1-32 model) and an oil rotary vacuum pump (SATO vacuum machinery, SW-150).
Results obtained were within Ϯ0.4% of the theoretical value. Materials used in the study were of commercial grades. SiO 2 (Kiesel 60, Merck) was used for column chromatography. Organic extracts were removed with a rotary evaporator under reduced pressure. N-[2-(Dimethylamino)ethyl]-7-nitro-9,10-dihydro-9-oxo-4-acridinecarboxamide (30b) CDI (6.25 g, 38.5 mmol) was added to a stirred solution of 7-nitro-9,10-dihydro-9-oxo-4-acridine carboxylic acid 17) a stirred solution of 30c (1.09 g, 3 .08 mmol) in DMF (50 ml) was added diisopropylethylamine (1.74 ml, 10 mmol) and ethyl chloroformate (0.96 ml, 10 mmol) at 0°C and the mixture was stirred for 6 h at r.t. H 2 O was added to the reaction mixture, which was extracted with EtOAc-THF solution (1 : 1 in volume) and the organic layer was washed with brine and then concentrated in vacuo. 
7-Acetylamino-N-[2-(dimethylamino)ethyl]-9,10-dihydro-9-oxo-4-acridinecarboxamide Hydrochloride (27)
A mixture of 8 (20 mg, 0.047 mmol) and K 2 CO 3 (50 mg) in MeOH (2 ml) and H 2 O (2 ml) was stirred for 1 h. After additing ammonium chloride (200 mg) the mixture was concentrated in vacuo untill most of MeOH was evaporated. The mixture was extracted with EtOAc-THF solution (1 : 1 in volume). The organic layer was washed successively with H 2 O and dried over MgSO 4 before evaporation. EtOH (0.4 ml) and an excess amount of 1 N HCl (aq.) were added to the residue and then concentrated in vacuo. The residue was recrystallized from EtOH-isopropyl ether to yield 10 mg of the title compound as yellow crystals (10 mg, 0.025 mmol, 53%), mp 278-280°C (dec.) (EtOH-isopropyl ether). 1 
N-[2-(Dimethylamino)ethyl]-7-nitro-10H-phenoxazine-1-carboxamide
(36) DMF (0.5 ml) and phosphorus trichloride (2 ml) was added to a suspension of 35 (435 mg, 1.60 mmol) in chloroform (CHCl 3 ) (15 ml) and then, the mixture was stirred overnight at r.t. The mixture was then concentrated in vacuo. Toluene was added to the mixture, which was again concentrated in vacuo. The residue was dissolved in CH 2 Cl 2 (10 ml) and treated with a solution of N,N-dimethylethylenediamine (1.0 ml, 9.1 mmol) in CH 2 Cl 2 (20 ml) and stirred overnight at r.t. NaHCO 3 (aq.) was added to the mixture and the mixture was extracted with CH 2 Cl 2 . The organic layer was filterd through celite and the filtrate was washed with H 2 O and brine, dried over MgSO 4 21) A solution of cyclohexanone 37 (10.4 ml, 0.100 mol) in AcOH (20 ml) was dropped into a stirred suspension of 2-hydrazinobenzoic acid hydrochloride 38 (19.8 g, 0.105 mol) in AcOH (180 ml) at 80°C and the mixture was stirred under reflux for 6 h, and allowed to stand at r.t. N-[2-(Dimethylamino)ethyl]-3-nitro-9H-carbazole-1-carboxamide (40c) A solution of potassium nitrate (1.01 g, 10.0 mmol) in H 2 SO 4 (2.5 ml) was added dropwise to a stirred solution of 39a (2.0 g, 9.5 mmol) in AcOH (250 ml) at 0°C. After stirring overnight at r.t., H 2 O was slowly added to the mixture. The precipitate was collected and washed with H 2 O and dried in vacuo to yield 2.3 g of crude product which was subsequently dissolved in DMF (100 ml). The solution was treated with CDI (2.9 g, 18 mmol), and stirred for 2 h. The reaction mixture was treated with N,N-dimethylethylenediamine (4.0 ml, 36 mmol), stirred overnight before addition of H 2 O. The mixture was extracted with EtOAc-THF solution (1 : 1 in volume). The organic layer was washed successively with H 2 O, NaHCO 3 (aq.), and brine and then concentrated in vacuo. 8 mmol) in DMF (200 ml) and the mixture was stirred for 1 h at r.t. under nitrogen atmosphere. Then the mixture was added a solution of ethyl chloroformate (3.8 ml, 40 mmol) in CH 2 Cl 2 (10 ml) at 0°C and stirred for 30 min at the same temperature. The reaction mixture was acidified with 1 N HCl (aq.) and the precipitate was collected before recrystallization from EtOH to yield the title compound as pale yellow crystals (5.54 g, 14.2 mmol, 80%), mp 288-290°C (dec.) (EtOH). ) and 50% Pd-C (550 mg) in AcOH (200 ml) and 1 N HCl (aq.) (50 ml) was stirred under 1 atm of hydrogen overnight. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The residue was treated with H 2 O and NaHCO 3 (aq.), and then the mixture was extracted with EtOAc. The organic layer was washed successively with H 2 O and brine and dried over MgSO 4 before being concentrated in vacuo. The residual solid was recrystallized from EtOH to yield 44b (3.74 g, 12 mmol, 81%) as yellow crystals. Compound 44b (430 mg, 1.3 mmol) was suspended in EtOH (20 ml) and 1 N HCl (aq.) was added and stirred overnight. The precipitate obtained was collected by filtration to yield the title compound 14 (480 mg, 100%) as pale yellow crystals, mp 281-283°C (dec.) (EtOH).
44b (Free (20 ml) and the mixture was stirred for 20 min at 0°C. After addition of methyl iodide (0.003 ml, 0.05 mmol), the mixture was stirred for 1 h at 0°C, and then acidified with 1 N HCl (aq.). The mixture was neutralized with NaHCO 3 (aq.), which was extracted with EtOAc-THF solution (1 : 1 in volume). The organic layer was washed successively with H 2 O and brine and then dried over MgSO 4 and the organic layer was concentrated in vacuo. The solid obtained was washed with isopropyl ether and EtOH to furnish the title compound as a free base, which was hydrochlorinated in a usual manner to yield the title compound as an orange solid (6.0 mg, 0.016 mmol, 32%), mp 280-281°C (dec.) (EtOH). 6-Acetyl-9H-carbazole-1-carboxylic Acid (46a) Acetic anhydride (0.208 ml, 2.20 mmol) was added to a stirred suspension of AlCl 3 (0.880 g, 6.60 mmol) in dry CHCl 3 (12 ml) with stirring and then a suspension of 39a (422 mg, 2.00 mmol) in dry CHCl 3 (4 ml) was added to the mixture at 0°C. After being allowed to stand at r.t. and stirred overnight. Then, the reaction mixture was poured into ice-water and an excess amount of 1 N HCl (aq.) was added and the mixture was extracted with EtOAc-THF solution (1 : 1 in volume). Organic layer was separated and NaHCO 3 (aq.) was added to the organic layer until the aqueous phase was neutralized to pH 7. The organic layer was separated and washed successively with H 2 O and brine, and dried over MgSO 4 
